Types segmentation differentiates the methodological approaches employed to detect adventitious contaminants, each with distinct validation pathways and cost structures. Molecular methods dominate the market, comprising PCR‑based assays (quantitative PCR, digital PCR) and next‑generation sequencing (targeted panels, whole‑genome sequencing). PCR techniques offer rapid, quantitative detection of known viral genomes and are preferred for routine release testing, while digital PCR improves sensitivity for low‑titer agents. NGS provides unbiased discovery of novel or unexpected contaminants, supporting comprehensive safety assessments in gene‑therapy vector production. Cell‑based assays include cytopathic‑effect (CPE) observation and reporter‑gene systems; these platforms detect functional infectivity and are indispensable for confirming the absence of replication‑competent viruses that may escape nucleic‑acid‑based screens. In‑vivo models, such as murine inoculation and non‑human‑primate studies, remain the gold standard for confirming sterility and pathogenicity, particularly when regulatory agencies demand demonstration of biological relevance. By allocating resources across these sub‑types, manufacturers align testing intensity with product risk, thereby shaping the overall market taxonomy for adventitious agent testing.
